In vitro and in vivo characterization of new molecular targets for the treatment of Acute Promyelocytic Leukemia

Summarise with VIRAT
Authors: Maria Franza
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Acute promyelocytic leukemia (APL) is an aggressive subtype of acute myeloid leukemia (AML), accounting for around 10–15% of cases. Ninety percent of APL patients have the reciprocal and balanced chromosomal translocation t(15;17), which determines the heterozygous expression of the PML-RARα oncoprotein fusion protein. The expression of this oncoprotein is necessary and sufficient for the onset of the disease as it acts through a dominant-negative mechanism with respect to wild-type PML and RARα proteins. PML-RARα specifically causes the maturation of myeloid progenitors (promyelocytes) to arrest by interfering with the gene transcription regulation necessary for the differentiation of leukemic blasts, as it inhibits the transcriptional function of the retinoic acid receptor α (RARα). Furthermore, PML-RARα negatively interferes with the polymerization of PML proteins, resulting in the impaired formation of PML nuclear bodies (PML-NBs). An effective therapeutic approach for treating APL involves administering

Fields of Study & Subjects

Retinoids in leukemia and cellular processes Acute Myeloid Leukemia Research Peroxisome Proliferator-Activated Receptors

Publication details

Journal / source
Iris (Roma Tre University)
Publication date
27 April 2026
Language
EN
Document type
Thesis